December 18, 2025- Pfizer Inc. provided its full-year 2026 guidance while revising its November 4, 2025 full-year 2025 Revenue guidance and reaffirming all other components of full-year 2025 financial guidance. The accompanying presentation can be found at www.pfizer.com/investors. Pfizer anticipates full-year 2026 revenues to be in the range of $59.5 to $62.5 billion, while full-year 2025 revenue guidance is revised to approximately $62.0 billion from the range of $61.0 to $64.0 billion previously. Full-year 2026 revenue guidance includes the expectation of revenues from our COVID-19 products being approximately $1.5 billion lower than what is expected in 2025 plus an expected year-over-year negative revenue impact of approximately $1.5 billion due to certain products experiencing loss of exclusivity (LOE). Pfizer expects full-year 2026 operational revenue growth at the midpoint, excluding both COVID-19 and LOE products, to be approximately 4% year-over-year.